Mutations in genes lpxL1 , bamA , and pmrB impair the susceptibility of cystic fibrosis strains of Pseudomonas aeruginosa to murepavadin

• Published in: Antimicrobial agents and chemotherapy Vol. 68; no. 1; p. e0129823
• Main Authors: Ghassani, Aya, Triponney, Pauline, Bour, Maxime, Plésiat, Patrick, Jeannot, Katy
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 10.01.2024
• Subjects: Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Antimicrobial Chemotherapy; Colistin - pharmacology; Colistin - therapeutic use; Cystic Fibrosis - drug therapy; Humans; Life Sciences; Mechanisms of Resistance; Microbial Sensitivity Tests; Mutation - genetics; Pseudomonas aeruginosa; Pseudomonas Infections - complications; Pseudomonas Infections - drug therapy; Respiratory Aerosols and Droplets; Tobramycin - pharmacology; antimicrobial resistance; Pseudomonas aeruginosa; murepavadin

Murepavadin is a peptidomimetic exhibiting specific inhibitory activity against species. In the present study, its activity was assessed on 230 cystic fibrosis (CF) strains of isolated from 12 French hospitals, in comparison with 12 other antipseudomonal antibiotics. Although murepavadin is still in...